Literature DB >> 3293527

Ribavirin small-particle-aerosol treatment of influenza B virus infection.

D I Bernstein1, P D Reuman, J R Sherwood, E C Young, G M Schiff.   

Abstract

In a randomized double-blind trial of aerosolized ribavirin for the treatment of influenza B virus infection, no significant difference was found in the febrile course or symptom score of the ribavirin-treated versus placebo-treated patients. The apparent lack of efficacy in this study as compared with that in previous studies is unexplained.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3293527      PMCID： PMC172268          DOI： 10.1128/AAC.32.5.761

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

2.  Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections.

Authors:  W J Rodriguez; R H Bui; J D Connor; H W Kim; C D Brandt; R H Parrott; B Burch; J Mace
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Ribavirin aerosol treatment of influenza B virus infection.

Authors:  H W McClung; V Knight; B E Gilbert; S Z Wilson; J M Quarles; G W Divine
Journal:  JAMA       Date:  1983-05-20       Impact factor: 56.272

4.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

5.  Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.

Authors:  B E Gilbert; S Z Wilson; V Knight; R B Couch; J M Quarles; L Dure; N Hayes; G Willis
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191
  5 in total
  5 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  Deconstructing nucleotide binding activity of the Mdm2 RING domain.

Authors:  Christina Priest; Carol Prives; Masha V Poyurovsky
Journal:  Nucleic Acids Res       Date:  2010-07-29       Impact factor: 16.971

Review 3.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 4.  Antiviral therapy for respiratory tract infections.

Authors:  Samson S Y Wong; Kwok-Yung Yuen
Journal:  Respirology       Date:  2008-11       Impact factor: 6.424

Review 5.  Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.

Authors:  Fernanda Andrade; Diana Rafael; Mafalda Videira; Domingos Ferreira; Alejandro Sosnik; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2013-08-07       Impact factor: 15.470
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.